Brainsway

Company Overview

Snapshot

Founded in January 2003 by Avner Hagai, Yiftach Roth, David Zacut, and Abraham Zangen, Brainsway operates with 51–200 employees. The company has raised $79.95 million across 6 funding rounds from 6 investors. In September 2024, Brainsway announced a US$20 million private placement with Valor Equity Partners.

Business overview

Brainsway develops advanced noninvasive neurostimulation treatments for mental health disorders, leveraging its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology. The company's technology, based on patents filed by the US National Institutes of Health (NIH) and BrainsWay, holds an exclusive license from the NIH. Brainsway's solutions are FDA cleared for major depressive disorder (including anxious depression), obsessive-compulsive disorder (OCD), and smoking addiction, and are approved in Canada for major depressive disorder. The company also holds CE Mark clearance for additional psychiatric and neurological conditions including post-traumatic stress disorder and Alzheimer's disease, serving hospitals, clinics, and healthcare providers globally.

Strategic signal

In September 2025, BrainsWay received FDA clearance for an accelerated Deep TMS protocol for the non-invasive treatment of Major Depressive Disorder (MDD). This regulatory approval signals a significant advancement in the accessibility and efficiency of their core therapy, potentially broadening market adoption and reinforcing the company's leadership in neurostimulation treatments for mental health.

Company Intelligence Q&A

What was a significant recent regulatory achievement for BrainsWay?

In September 2025, BrainsWay received FDA clearance for an accelerated Deep TMS protocol for the non-invasive treatment of Major Depressive Disorder (MDD), indicating a faster treatment option for patients.

What was BrainsWay's most recent funding activity?

In September 2024, BrainsWay announced a US$20 million private placement with Valor Equity Partners.

What strategic expansion did BrainsWay undertake in East Asia?

In October 2024, BrainsWay further penetrated East Asia with the placement of 15 additional Deep TMS™ systems in Taiwan and South Korea, expanding its global reach.

What recent development occurred regarding PTSD treatment in Israel?

In September 2024, the Israel Ministry of Defense cleared BrainsWay Deep TMS™ for PTSD reimbursement at Israeli hospitals, potentially increasing access to treatment for veterans and others.

What was a key strategic partnership announced by BrainsWay in the US?

In September 2023, BrainsWay forged a strategic partnership with a treatment provider in the Northeast U.S., aiming to broaden access to its Deep TMS technology.